TRINETRA › Sectors › Healthcare
Mankind Pharma Limited (MANKIND) — share price, P/E and fundamentals
Mankind Pharma Limited (NSE: MANKIND) closed at ₹2,492.80 on 30 Oct 2026, +0.7% over one year, against a 52-week range of ₹1,909.70 – ₹2,642.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 26 Oct 2026) it reported revenue of ₹4,338 cr and net profit of ₹711 cr, a 16.4% net margin; revenue grew 17.3% and profit grew 48.9% year on year.
On four consecutive filed quarters its trailing P/E is 45.5; since 21 May 2025 its own P/E has ranged from 39.2 to 56.5 (median 48.4), and today's reading is higher than 31% of those 357 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 16.2%, ROCE 17.9%, debt-to-equity 0.31, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 62% of 63 sector peers; PBT margin higher than 62% of 63 sector peers; ROE higher than 65% of 63 sector peers.
Key figures
| Last close | ₹2,492.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -0.3% / +9.9% / +0.7% |
| 52-week low – high | ₹1,909.70 – ₹2,642.00 |
| Market capitalisation | ₹1,02,953 cr |
| Trailing P/E | 45.5 |
| Price / book | 5.86 |
| EV / EBITDA | 25.1 |
| Earnings yield | 2.2% |
| TTM EPS | ₹54.81 |
| TTM net profit | ₹2,264 cr |
| Quarter revenue | ₹4,338 cr |
| Quarter net profit | ₹711 cr |
| Net margin | 16.4% |
| Revenue growth (YoY) | +17.3% |
| Profit growth (YoY) | +48.9% |
| Return on equity | 16.2% |
| ROCE | 17.9% |
| Debt / equity | 0.31 |
| Current ratio | 1.37 |
| Free cash flow | ₹1,409 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹94.8 cr |
Against Healthcare peers
| Metric | MANKIND | Peer median | Percentile |
|---|---|---|---|
| Net margin | 16.40 | 12.67 | 62 |
| PBT margin | 21.33 | 17.57 | 62 |
| ROE | 16.19 | 13.86 | 65 |
| ROCE | 17.87 | 16.59 | 54 |
| Debt / equity | 0.31 | 0.11 | 73 |
| FCF margin | 16.84 | -0.87 | 71 |
| Cash conversion | 1.41 | 1.25 | 62 |
| Trailing P/E | 45.48 | 43.07 | 53 |
Questions
What is the P/E ratio of Mankind Pharma Limited?
Mankind Pharma Limited's trailing P/E is 45.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 21 May 2025 its P/E has ranged 39.2–56.5.
What were Mankind Pharma Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Mankind Pharma Limited reported revenue of ₹4,338 cr and net profit of ₹711 cr (consolidated), filed with the exchange on 26 Oct 2026.
What is Mankind Pharma Limited's ROE?
Return on equity is 16.2% based on the balance sheet dated 30 Sept 2026.
Does Mankind Pharma Limited have debt?
Debt-to-equity is 0.31 on the balance sheet dated 30 Sept 2026.
What is MANKIND's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, MANKIND traded between ₹1,909.70 and ₹2,642.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.